V ariable degrees of coronary microvascular dysfunction occur at the time of ST-segment-elevation myocardial infarction (STEMI) correlating with infarct size and long-term prognosis. Angiographic methods for assessing microvascular dysfunction in the cardiac catheterization laboratory at the time of STEMI include thrombolysis in myocardial infarction flow grade, thrombolysis in myocardial infarction frame count, and thrombolysis in myocardial infarction myocardial perfusion grade. 1 More recently, coronary wire-based methods measuring Doppler-derived parameters, such as the coronary flow velocity reserve (CFVR), or measuring thermodilutionderived parameters, such as the index of microcirculatory resistance, have been shown to be more powerful predictors of acute left ventricular dysfunction, myocardial viability, and subsequent adverse outcomes. 2,3
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Although it is widely accepted that the degree of microvascular dysfunction occurring in the myocardium subtended by the infarct-related vessel correlates with infarct size and prognosis, there has been some debate on whether more global microvascular dysfunction, involving myocardial regions not supplied by the infarct-related vessel, is present at the time of STEMI. For example, Uren et al 4 performed positron emission tomography imaging in 13 patients with STEMI and found a decreased coronary flow reserve in the noninfarct-related vessel, which improved at 6-month follow-up. However, Ntalianis et al 5 measured fractional flow reserve in a nonculprit vessel at the time of STEMI in 75 patients and again 1 month later and found no significant difference in fractional flow reserve or in index of microcirculatory resistance, which was measured in a subgroup, suggesting that the microvascular dysfunction resulting from STEMI is limited to the territory supplied by the infarct-related artery.
In this issue of Circulation: Cardiovascular Interventions, van de Hoef et al 6 report long-term follow-up in 100 patients presenting with STEMI, in whom they measured Doppler wire-derived CFVR, diastolic deceleration time, and systolic flow reversal in both the infarct-related artery and a nonculprit reference vessel. They found that the mean CFVR value in the infarct-related vessel was 1.6±0.4 and in the nonculprit vessel, it was 2.4±0.5. A normal CFVR value is generally thought to be >2.0. Interestingly, they found that CFVR in the nonculprit reference artery was an independent predictor of long-term cardiac mortality (hazard ratio, 4.1; 95% confidence interval, 1.2-14.2). On the basis of receiver operator characteristic curve analysis, 2.1 was the best cutoff value, with 35% of patients having a CFVR value below this cut point in the nonculprit vessel. The diastolic deceleration time, presence or absence of systolic flow reversal, and the CFVR measured in the infarct-related artery surprisingly were not predictive of long-term cardiac mortality.
The implications of the findings are that microvascular dysfunction in the setting of STEMI can be global, and may not only involve the infarct-related territory. Furthermore, these data suggest that the presence of more widespread microvascular dysfunction is a powerful predictor of long-term adverse outcome, more powerful than identifying infarct-related artery microvascular dysfunction. To put these findings into context, we should review some aspects of the study in more detail.
First, there are some limitations of this study that are worth noting. It was a single-center, retrospective analysis, including only anterior STEMI, excluding patients with 3-vessel coronary disease and including patients recruited between 1997 and 2000. Although the recruitment timeframe is necessary for performing long-term follow-up, this means that contemporary therapy, such as universal stenting, newer and longer term antiplatelet therapy, and thrombus aspiration were not routinely performed. This may explain the observation that, despite recruiting relatively low-risk patients, thrombolysis in myocardial infarction-3 flow was achieved in only 75% of patients and normal myocardial blush grade was achieved in only 52% of patients. With more current treatment, patients might have incurred less microcirculatory dysfunction weakening the association between microvascular impairment and outcome in the nonculprit vessel.
Another limitation stems from basing the definition of the cut point for an abnormal reference vessel CFVR on retrospective analysis of the receiver operator characteristic curve, instead of prospectively choosing a value; this biases the results in favor of the reference vessel CFVR. We are not provided with information on how many patients were screened during the enrollment period but found to be ineligible, which would help us understand the applicability of these findings. We do know that routine placement of a Doppler wire in a nonculprit vessel at the time of STEMI to measure CFVR is a practical challenge. Finally, we are not provided with information about the medical regimen patients received after their STEMI, the symptom to reperfusion or door to balloon time, or about other adverse events during follow-up, such as myocardial infarction or congestive heart failure, all of which may have impacted the results.
Another aspect of this study worth reviewing is the technique used to assess microvascular function. Doppler wirederived CFVR is defined as the hyperemic coronary velocity divided by the resting coronary velocity and is a measurement which interrogates both the epicardial and the microcirculatory components of the coronary circulation ( Figure) . A low CFVR may indicate the presence of significant epicardial stenosis, microcirculatory dysfunction, or both. Moreover, CFVR is inherently limited by its reliance on resting coronary velocity or flow, which changes from minute to minute depending on the hemodynamic conditions present. Measurements, which specifically interrogate the microcirculation and are independent of hemodynamic changes, such as the thermodilution-derived index of microcirculatory resistance 3 or the Doppler-derived microvascular resistance index, 7 would have been preferable. The authors present a hyperemic microvascular resistance measurement in the tables but do not clarify whether this measurement was predictive of mortality.
These limitations of CFVR may explain in part why the investigators did not find a relationship between the infarctrelated artery CFVR and cardiac mortality. For example, index of microcirculatory resistance has been shown to be predictive of outcomes when measured in the infarct-related artery at the time of STEMI, whereas coronary flow reserve has not. 3, [8] [9] [10] Another potential explanation for the lack of prognostic power of CFVR may be that it lacks the quantitative ability to distinguish infarct size, with the lowest value of 1.0 occurring with moderate-sized infarcts and larger ones. Finally, the study may have been underpowered to observe a significant correlation between infarct-related artery CFVR and cardiac mortality because there was a statistical trend (P=0.10). The small sample size may also explain why the diastolic deceleration time and the presence of systolic flow reversal in the infarctrelated artery did not predict mortality, whereas they have in other studies. 11, 12 What remains unclear from this study is why some patients had a low CFVR in the nonculprit vessel and why this was predictive of adverse outcomes. Perhaps, the most likely explanation is that CFVR in the nonculprit vessel may be a reflection of the effects of a larger infarction on the wall motion in remote territories, the left ventricular end-diastolic pressure, and the neurohumoral response, all of which have been implicated in changes in coronary flow. 13 The significantly higher creatine kinase-MB fraction values in the patients with low nonculprit vessel CFVR would argue in favor of this explanation. Alternatively, although the investigators excluded patients with visually determined angiographic stenosis in the nonculprit vessel, a significant proportion of angiographically normal-appearing coronary arteries harbors physiologically significant disease. 14 It is conceivable that the association between low-reference vessel CFVR and long-term mortality is partly related to epicardial coronary disease burden. Finally, the abnormal CFVR in the nonculprit vessel may be a marker of preexistent microvascular dysfunction, which has been associated with adverse outcomes. 15 The association between microcirculatory impairment and prognosis after STEMI provides an opportunity for translation into clinical use. STEMI is a common cause of morbidity and mortality. A method to predict adverse outcomes, which can be performed in the cardiac catheterization laboratory after primary percutaneous coronary intervention, would enable identification of an enriched population for trials of acute adjunctive therapy. The results of this study and others demonstrate that an invasive coronary wire-based assessment of microvascular function could be one such method.
Several adjunctive therapies have been investigated in an attempt to improve STEMI outcomes, but have had disappointing results. 16 Perhaps, future studies should focus these therapies only on patients with larger degrees of infarct-related coronary microvascular dysfunction. Whether microvascular dysfunction at the time of STEMI is a local or more global phenomenon likely depends on the size of the infarction, with a more global effect in larger ones. Whether routine assessment of the nonculprit microvascular territory is warranted will require further study. Incorporating the assessment of the coronary microcirculation into the management algorithm in patients with STEMI could potentially provide a new paradigm in the hope of benefiting these patients.
